Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Asieris Acquires Rights to Heart Failure Therapy from Acorda

publication date: Aug 31, 2022

Shanghai Asieris Pharma acquired rights to nepicastat, a small molecule drug that may be an effective therapy for heart failure, from Acorda Therapeutics in a $7.5 million agreement. Asieris will have rights to all non-psychiatric indications of the drug. Acorda acquired nepicastat when it bought Biotie Pharma, a Finnish company, in 2016. Originally, Acorda developed the candidate as a therapy for cocaine addiction and PTSD, though clinical trials were not successful. Acorda will receive an upfront payment of $500,000, and up to $7 million in milestones, plus royalties. More details....

Stock Symbols: (SHA: 688176) (NSDQ: ACOR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital